The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

post
What Does Syner-G’s Technical and Quality Assurance Team Do?
Read More

post
Empowering and Encouraging Innovation: The Advantages of the FDA’s Orphan Drug Designation for Drug Companies and Patients
Read More

case-study
Establishment of a Long-Term Medical Writing Partnership
Read More

case-study
Expert Regulatory Affairs Services for a European-Based Client
Read More
Let's move from science to success.
Let’s Talk